Pfizer’s Abrilada (biosimilar, adalimumab) Receives the US FDA’s Approval for Rheumatoid Arthritis

 Pfizer’s Abrilada (biosimilar, adalimumab) Receives the US FDA’s Approval for Rheumatoid Arthritis

Pfizer’s Abrilada (biosimilar, adalimumab) Receives the US FDA’s Approval for Rheumatoid Arthritis

Shots:

  • The US FDA approval is based on the clinical study assessing Abrilada (adalimumab-afzb) vs reference product, AbbVie’s Humira in 597 biologic-naïve patients with rheumatoid arthritis for 78 wks.
  • Result: @26wks. patients achieved ACR20 (68.7% vs 72.7%) with a treatment difference of −3.98%, ACR20, 50, and 70 rates were similar with both groups
  • The approval of Abrilada, a biosimilar to Humira foster the biologics competition in the US as it marks the 9th biosimilar product to be approved in the US in 2019, bringing the overall total of biosimilar approvals to 25

Click here to­ read full press release/ article | Ref: FDA | Image: Financial Express

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post